Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Nuclear Medicine
Published in: Annals of Nuclear Medicine 1/2011

01-01-2011 | Original Article

The potential of FDG-PET/CT for detecting prostate cancer in patients with an elevated serum PSA level

Authors: Ryogo Minamimoto, Hiroji Uemura, Futoshi Sano, Hideyuki Terao, Yoji Nagashima, Shoji Yamanaka, Kazuya Shizukuishi, Ukihide Tateishi, Yoshinobu Kubota, Tomio Inoue

Published in: Annals of Nuclear Medicine | Issue 1/2011

Login to get access

Abstract

Purpose

The aim of this study is to evaluate the potential and limitation of FDG-PET/CT for detecting prostate cancer in subjects with an elevated serum prostate-specific antigen (PSA) level. Although [18F]-2-fluoro-2-deoxyglucose positron emission tomography (FDG-PET) has limited value in detecting prostate cancer, the potential of PET/CT has not been precisely evaluated, since positron emission tomography/computed tomography (PET/CT) provides accurate localization of functional findings obtained by PET.

Methods

Subjects with an increasing PSA level suggestive of prostate cancer were enrolled in this study. FDG-PET/CT was performed prior to prostate biopsy and the findings were compared with the pathological results.

Results

Fifty subjects with an elevated serum PSA level took part in this study. The sensitivity, specificity and positive predictive value (PPV) of FDG-PET/CT in the prostate were 51.9% (27/52 areas), 75.7% (112/148 areas) and 42.9% (27/63 areas), respectively; those in the peripheral zone were 73.3% (22/30 areas), 64.3% (45/70 areas) and 46.8% (22/47 areas), respectively; and those in the central gland were 22.7% (5/22 areas), 85.9% (67/78 areas) and 31.3% (5/16 areas), respectively. The estimated cut-off values according to the highest odds ratio (OR) were age of 70 years [OR: 7.00, 95% confidence interval (CI): 1.89–25.93] and a PSA value of 12.0 ng/ml (OR: 10.77, 95% CI: 2.78–41.74). The FDG-PET/CT could potentially detect cancer with 80.0% sensitivity and 87.0% PPV in cases with a Gleason score of 7 or greater.

Conclusion

FDG-PET/CT was appropriate for detecting peripheral zone prostate cancer in patients at more than an intermediate risk.
Literature
1.
Kim EE, Lee MC, Inoue T, Wong WH. Clinical PET: principles and applications. New York: Springer; 2003. p. 247–386.
2.
Powles T, Murray I, Brock C, Oliver T, Avril N. Molecular positron emission tomography and PET/CT imaging in urological malignancies. Eur Urol. 2007;51:1511–20.CrossRefPubMed
3.
Kotzerke J, Prang J, Neumaier B, et al. Experience with carbon-11 choline positron emission tomography in prostate carcinoma. Eur J Nucl Med. 2000;27:1415–9.CrossRefPubMed
4.
Kwee SA, Coel MN, Lim J, Ko JP. Prostate cancer localization with 18fluorine fluorocholine positron emission tomography. J Urol. 2005;173:252–5.CrossRefPubMed
5.
Kotzerke J, Volkmer BG, Neumaier B, Gschwend JE, Hautmann RE, Reske SN. Carbon-11 acetate positron emission tomography can detect local recurrence of prostate cancer. Eur J Nucl Med Mol Imaging. 2002;29:1380–4.CrossRefPubMed
6.
Wahl RL. Principles and practice of PET and PET/CT second edition. Philadelphia: Lippincott Williams & Wilkins; 2009. p. 47–57.
7.
Partin AW, Kattan MW, Subong EN, et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA. 1997;277:1445–51.CrossRefPubMed
8.
Hricak H, Choyke PL, Eberhardt SC, Leibel SA, Scardino PT. Imaging prostate cancer: a multidisciplinary perspective. Radiology. 2007;243:28–53.CrossRefPubMed
9.
Mirowitz SA, Hammerman AM. CT depiction of prostatic zonal anatomy. J Comput Assist Tomogr. 1992;16:439–41.CrossRefPubMed
10.
Effert PJ, Bares R, Handt S, Wolff JM, Büll U, Jakse G. Metabolic imaging of untreated prostate cancer by positron emission tomography with 18fluorine-labeled deoxyglucose. J Urol. 1996;155:994–8.CrossRefPubMed
11.
Sung J, Espiritu JI, Segall GM, Terris MK. Fluorodeoxyglucose positron emission tomography studies in the diagnosis and staging of clinically advanced prostate cancer. BJU Int. 2003;92:24–7.CrossRefPubMed
12.
Oyama N, Akino H, Suzuki Y, et al. The increased accumulation of [18F]fluorodeoxyglucose in untreated prostate cancer. Jpn J Clin Oncol. 1999;29:623–9.CrossRefPubMed
13.
Liu IJ, Zafar MB, Lai YH, Segall GM, Terris MK. Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer. Urology. 2001;57:108–11.CrossRefPubMed
14.
Chandler JD, Williams ED, Slavin JL, Best JD, Rogers S. Expression and localization of GLUT1 and GLUT12 in prostate carcinoma. Cancer. 2003;97:2035–42.CrossRefPubMed
15.
Effert P, Beniers AJ, Tamimi Y, Handt S, Jakse G. Expression of glucose transporter 1 (Glut-1) in cell lines and clinical specimens from human prostate adenocarcinoma. Anticancer Res. 2004;24:3057–63. (Abstract only).PubMed
16.
Zelhof B, Pickles M, Liney G, et al. Correlation of diffusion-weighted magnetic resonance data with cellularity in prostate cancer. BJU Int. 2009;103:883–8.CrossRefPubMed
17.
Catalona WJ, Partin AW, Slawin KM, et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA. 1998;279:1542–7.CrossRefPubMed
18.
Lee R, Localio AR, Armstrong K, Malkowicz SB, Schwartz JS. A meta-analysis of the performance characteristics of the free prostate-specific antigen test. Urology. 2006;67:762–8.CrossRefPubMed
19.
Catalona WJ, Southwick PC, Slawin KM, et al. Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging. Urology. 2000;56:255–60.CrossRefPubMed
20.
Aksoy Y, Oral A, Aksoy H, Demirel A, Akcay F. PSA density and PSA transition zone density in the diagnosis of prostate cancer in PSA gray zone cases. Ann Clin Lab Sci. 2003;33:320–3.PubMed
21.
Horninger W, Reissigl A, Klocker H, et al. Improvement of specificity in PSA-based screening by using PSA-transition zone density and percent free PSA in addition to total PSA levels. Prostate. 1998;37:133–7.CrossRefPubMed
22.
Barry MJ. Clinical practice. Prostate-specific-antigen testing for early diagnosis of prostate cancer. N Engl J Med. 2001;344:1373–7.CrossRefPubMed
23.
Wefer AE, Hricak H, Vigneron DB, et al. Sextant localization of prostate cancer: comparison of sextant biopsy, magnetic resonance imaging and magnetic resonance spectroscopic imaging with step section histology. J Urol. 2000;164:400–4.CrossRefPubMed
24.
Simardi LH, Tobias-MacHado M, Kappaz GT, Taschner Goldenstein P, Potts JM, Wroclawski ER. Influence of asymptomatic histologic prostatitis on serum prostate-specific antigen: a prospective study. Urology. 2004;64:1098–101.CrossRefPubMed
25.
Kawakami J, Siemens DR, Nickel JC. Prostatitis and prostate cancer: implications for prostate cancer screening. Urology. 2004;64:1075–80.CrossRefPubMed
26.
27.
Loeb S, Gashti SN, Catalona WJ. Exclusion of inflammation in the differential diagnosis of an elevated prostate-specific antigen (PSA). Urol Oncol. 2009;27:64–6.PubMed
28.
Serretta V, Catanese A, Daricello G, et al. PSA reduction (after antibiotics) permits to avoid or postpone prostate biopsy in selected patients. Prostate Cancer Prostatic Dis. 2008;11:148–52.CrossRefPubMed
Metadata
Title
The potential of FDG-PET/CT for detecting prostate cancer in patients with an elevated serum PSA level
Authors
Ryogo Minamimoto
Hiroji Uemura
Futoshi Sano
Hideyuki Terao
Yoji Nagashima
Shoji Yamanaka
Kazuya Shizukuishi
Ukihide Tateishi
Yoshinobu Kubota
Tomio Inoue
Publication date
01-01-2011
Publisher
Springer Japan
Published in
Annals of Nuclear Medicine / Issue 1/2011
Print ISSN: 0914-7187
Electronic ISSN: 1864-6433
DOI
https://doi.org/10.1007/s12149-010-0424-4

Other articles of this Issue 1/2011

Annals of Nuclear Medicine 1/2011 Go to the issue

Original Article

Diagnostic role of initial renal cortical scintigraphy in children with the first episode of acute pyelonephritis

Review Article

Evaluation of 99mTc-labeled antibiotics for infection detection

Technical Note

Improvement of image resolution of brain SPECT by use of the wide-angle offset acquisition method

Original Article

Predictors of abnormal heart rate response to dipyridamole in patients undergoing myocardial perfusion SPECT

Original Article

Usefulness of the automatic quantitative estimation tool for cerebral blood flow: clinical assessment of the application software tool AQCEL

Case Report

Severe vasospastic angina with ventricular fibrillation suggested by iodine-123 beta-methyl-p-iodophenyl-pentadecanoic acid in a young woman